Informations

POLARGO Study Background and Design Polatuzumab vedotin is an antibody-drug conjugate (ADC) targeting CD79b. CD79b is an important component of the B-cell receptor complex and is highly expressed on the…

Challenges and Breakthroughs in Large B-cell Lymphoma Microenvironment Research Large B-cell Lymphoma (LBCL), as a highly heterogeneous malignant hematological tumor, has complex pathogenesis and significant differences in prognosis. Although targeted…

DLBCL Microenvironment Subtyping and Prediction of CAR-T-cell Therapy DLBCL, an aggressive B-cell non-Hodgkin lymphoma, can achieve long-term remission in some patients through standard treatments like R-CHOP, but approximately 30% of…

The completion and smooth relocation of the new Hebei Yanda Ludaopei Hospital campus mark a major step forward for the Ludaopei Medical Group’s clinical capacity. On this occasion, internationally renowned hematologist Professor Robert Negrin—Director of the Blood and Marrow Transplantation Program at Stanford University and President-Elect of the American Society of Hematology (ASH)—visited the hospital…

Treatment Dilemmas and the Emergence of Innovative Solutions For patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who are ineligible for curative treatments such as autologous stem cell…

POLARIX Trial: Breaking the Two-Decade Standoff in First-Line DLBCL Treatment Over the past two decades, numerous clinical trials have attempted to improve the prognosis of DLBCL patients by adding new…

Challenges in Relapsed/Refractory DLBCL Treatment and the Development Background of Suvatomib Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma in adults. Although first-line chemoimmunotherapy regimens have…

Mechanism of Action of Novel BTK Degrader Bexobrutideg and Unmet Needs Professor Alexey Danilov first introduced the mechanism of action of proteolysis-targeting chimeras (PROTACs) as a new class of drugs.…